A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2.
BACKGROUND
To date, all cases of familial partial lipodystrophy type 2 (FPLD2; Mendelian Inheritance in Man 151660) result from missense mutations in LMNA, which encodes nuclear lamin A/C (Mendelian Inheritance in Man 150330).


OBJECTIVE
The objective of the study was to carry out mutational analysis of LMNA in two sisters with a particularly severe FPLD2 phenotype.


METHODS
This was a descriptive case report with molecular studies.


METHODS
The study was conducted at a referral center.


METHODS
We report two sisters of South Asian origin. The first presented with acanthosis nigricans at age 5 yr, diabetes with insulin resistance, hypertension and hypertriglyceridemia at age 13 yr, and partial lipodystrophy starting at puberty. Her sister and their mother had a similar metabolic profile and physical features, and their mother died of vascular disease at age 32 yr.


METHODS
There were no interventions.


RESULTS
LMNA sequencing showed that the sisters were each heterozygous for a novel G>C mutation at the intron 8 consensus splice donor site, which was absent from the genomes of 300 healthy individuals. The retention of intron 8 in mRNA predicted a prematurely truncated lamin A isoform (516 instead of 664 amino acids) with 20 nonsense 3'-terminal residues. The mutant lamin A isoform failed to interact normally with emerin and failed to localize to the nuclear envelope.


CONCLUSIONS
This is the first LMNA splicing mutation to be associated with FPLD2, and it causes a severe clinical and metabolic phenotype.
Morel
Chantal F
CF
Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, London, Ontario, Canada.
Thomas
Mary Ann
MA
Cao
Henian
H
O'Neil
Caroline H
CH
Pickering
J Geoffrey
JG
Foulkes
William D
WD
Hegele
Robert A
RA
D000052:Acanthosis Nigricans / Q000150:complications / Q000235:genetics; D000328:Adult; D001208:Asia / Q000208:ethnology; D015153:Blotting, Western; D002170:Canada; D004252:DNA Mutational Analysis; D003923:Diabetes Mellitus, Lipoatrophic / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000235:genetics; D005260:Female; D005455:Fluorescent Antibody Technique; D006579:Heterozygote; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000235:genetics; D015228:Hypertriglyceridemia / Q000150:complications / Q000235:genetics; D007333:Insulin Resistance; D007438:Introns / Q000235:genetics; D034904:Lamin Type A / Q000235:genetics*; D008565:Membrane Proteins / Q000032:analysis / Q000378:metabolism; D008856:Microscopy, Fluorescence; D009154:Mutation; D009687:Nuclear Proteins; D010641:Phenotype; D012326:RNA Splicing / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D013946:Thymopoietins / Q000032:analysis / Q000378:metabolism; D014162:Transfection
C494847:LMNA protein, human; D034904:Lamin Type A; D008565:Membrane Proteins; D009687:Nuclear Proteins; D012333:RNA, Messenger; D013946:Thymopoietins; C092710:emerin